

FILE 'HCAPLUS' ENTERED AT 09:12:22 ON 22 DEC 2008

L1	1123946	S	IMMUN?
L2	800	S	DEXTRAN(6A)PHOSPH?
L3	31511	S	POLYPHOSPHATE OR POLYPHOSPHORIC
L4	13	S	L2 AND L3
L5	74419	S	MOLECULAR WEIGHT
L6	13	S	L2 AND L5
L7	10	S	L6 AND (PY<2003 OR AY<2003 OR PRY<2003)
L8	93	S	L1 AND L2
L9	69	S	L8 AND (PY<2003 OR AY<2003 OR PRY<2003)
L10	0	S	L9 AND L5
L11	4685617	S	DEGREE OR PHOSPHORYLATION
L12	5	S	L9 AND L11

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'HCAPLUS' ENTERED AT 09:12:22 ON 22 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2008 VOL 149 ISS 26
 FILE LAST UPDATED: 21 Dec 2008 (20081221/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s immun?
 L1 1123946 IMMUN?

=> s dextran(6a)phosph?
 40028 DEXTRAN
 1991335 PHOSPH?
 L2 800 DEXTRAN(6A)PHOSPH?

=> s polyphosphate or polyphosphoric
 16181 POLYPHOSPHATE
 20650 POLYPHOSPHORIC
 L3 31511 POLYPHOSPHATE OR POLYPHOSPHORIC

=> s l2 and l3
 L4 13 L2 AND L3

=> d l4 1-13 ti abs bib

L4 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Porous calcium phosphate bone material
 AB Porous calcium phosphate implant compns. that approx. the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compns. include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition When introduced at an implant site, the calcium phosphate compns. are remodeled into bone. Methods for using the calcium phosphate compns., e.g., to repair or replace bone, are also provided. Thus, amorphous calcium phosphate was prepared as follows. Solution

of disodium hydrogen phosphate heptahydrate 1000 g in distilled water 14.4 mL was prepared and stirred. To this solution, sodium hydroxide 555 g, sodium bicarbonate 333 g, and sodium pyrophosphate decahydrate 2.2 g were added sequentially to form solution 1. A solution of calcium nitrate tetrahydrate

208

g in 5.6 L of distilled water was prepared and of magnesium chloride hexahydrate 11 g was added to this solution to form solution 2. Solution 2 was quickly poured into solution 1 at room temperature and stirred for 1 min. The amorphous calcium phosphate precipitated immediately and completely.

AN 2007:619421 HCAPLUS <<LOGINID::20081222>>

DN 147:39252

TI Porous calcium phosphate bone material

IN Rosenberg, Aron D.; Gilles De Pelichy, Laurent D.; Bondre, Shrikar; Strunk, Michael

PA USA

SO U.S. Pat. Appl. Publ., 20pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070128245	A1	20070607	US 2005-294819	20051206
	AU 2006322025	A1	20070614	AU 2006-322025	20061206
	CA 2632785	A1	20070614	CA 2006-2632785	20061206
	WO 2007067561	A2	20070614	WO 2006-US46435	20061206
	WO 2007067561	A3	20071011		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1962716	A2	20080903	EP 2006-844849	20061206
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2005-294819	A	20051206		
	WO 2006-US46435	W	20061206		

L4 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Delayed-setting calcium phosphate pastes

AB The invention features delayed-setting calcium phosphate pastes which are useful for the preparation of delivery vehicles for biol. active agents, useful for the treatment of orthopedic conditions and can be stored for long periods without prematurely setting. For example, amorphous Ca phosphate and dicalcium phosphate dihydrate powders were mixed and ball-milled. The resultant powder was mixed with a methylpyrrolidone solvent containing DL-lactide-glycolide copolymer to give a paste.

AN 2005:1314368 HCAPLUS <<LOGINID::20081222>>

DN 144:57638

TI Delayed-setting calcium phosphate pastes

IN Lee, Dosuk D.; Rosenberg, Aron D.; Gilles De Pelichy, Laurent D.; Sutaria, Manish; Tofighi, Aliassghar N.

PA Etex Corporation, USA; Lee, Youngmi M.

SO PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005117919	A2	20051215	WO 2005-US12583	20050414
	WO 2005117919	A3	20070607		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA			
	AU 2005249365	A1	20051215	AU 2005-249365	20050414
	CA 2562675	A1	20051215	CA 2005-2562675	20050414
	EP 1742648	A2	20070117	EP 2005-778214	20050414
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007533376	T	20071122	JP 2007-508509	20050414
	KR 2007033970	A	20070327	KR 2006-723613	20061110
	US 20080028992	A1	20080207	US 2006-578337	20061226
PRAI	US 2004-562497P	P	20040415		
	WO 2005-US12583	W	20050414		

L4 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Dextran from Leuconostoc mesenteroides augments immunostimulatory effects by the introduction of phosphate groups

AB The immunol. effects of phosphorylated dextran (in which phosphate groups were chemical introduced) on murine splenocytes were examined When dextran produced by Leuconostoc mesenteroides was phosphorylated by a reaction with polyphosphoric acid in formamide solution for 48 h, the degree of phosphorylation of dextran was maximal. The highest phosphorus content (1.7%, wt/wt) was observed in 40 kDa of dextran. The mitogenic response of murine splenocytes was enhanced by the phosphorylated dextran, but its activity was not related to its mol. weight A strong response was detected at a concentration of 10 to

500 μ g/mL, and the highest activity was obtained 48 h after stimulation. Phosphorylated dextran was characterized as a B-cell-specific mitogen. The expressions of CD86 on CD8 α -CD11c- and CD8 α -CD11c+ cells were augmented by phosphorylated dextran. The levels of mRNA expression of gamma interferon and interleukin-10 on murine splenocytes were also increased by the stimulation. These results demonstrate that dextran exerts immunostimulation by the introduction of phosphate groups.

AN 2004:731155 HCAPLUS <<LOGINID::20081222>>

DN 142:5362

TI Dextran from Leuconostoc mesenteroides augments immunostimulatory effects by the introduction of phosphate groups

AU Sato, Toshihiro; Nishimura-Uemura, Junko; Shimosato, Takeshi; Kawai, Yasushi; Kitazawa, Haruki; Saito, Tadao

CS NOF Corporation, Shibuya-ku, Tokyo, 150-6019, Japan

SO Journal of Food Protection (2004), 67(8), 1719-1724
 CODEN: JFPRDR; ISSN: 0362-028X
 PB International Association for Food Protection
 DT Journal
 LA English
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Phosphorylated dextran as immunopotentiator
 AB It is clarified that an immunopotentiation activity can be imparted to dextran, which shows no immunol. activity, by chemical phosphorylating it. The phosphorylated dextran is a B cell mitogen, activates dendritic cells and induces IL-10 and IFN- γ . Thus, it is expected as being effective in preventing infectious diseases and colitis and preventing allergic diseases by maintaining the Th1/2 balance. Phosphorylated dextran was prepared from dextran and polyphosphoric acid, and its blastogenic effect on mouse spleen cells was examined
 AN 2004:80514 HCAPLUS <<LOGINID::20081222>>
 DN 140:151931
 TI Phosphorylated dextran as immunopotentiator
 IN Saito, Tadao; Kitazawa, Haruki
 PA Meiji Dairies Corporation, Japan
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009099	A1	20040129	WO 2003-JP9324	20030723
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004107316	A	20040408	JP 2003-50739	20030227
	AU 2003252244	A1	20040209	AU 2003-252244	20030723
	EP 1543833	A1	20050622	EP 2003-765361	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20060154896	A1	20060713	US 2005-522047	20051020
PRAI	JP 2002-213305	A	20020723		
	JP 2003-50739	A	20030227		
	WO 2003-JP9324	W	20030723		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Phosphorus-containing polymers for optical signal transducers
 AB Phosphorus-containing polymers suitable for coating dielec. surfaces are described by the general formulas P(A)m(F)n1(U)o1 (I) and P(A)m(UFn2)o2 (II) (P = (un)branched, (un)crosslinked homo- or heteropolymeric polymer component; A = identical or different phosphorus-containing groups bonded to P; m = .apprx.3-1000, F = identical or different functional groups bonded

directly or indirectly to P; n1 = .apprx.1-1000; n2 = .apprx.1-100, U = identical or different (un)branched (un)crosslinked oligomeric or polymeric segments made up of identical or different monomers which are bonded to P; o1 = .apprx.0-1000, o2 = .apprx.1-1000). Methods for preparing the polymers are described which entail copolymering a monomer containing a phosphorus-containing group A, or a plurality of identical or different monomers containing identical or different phosphorus-containing groups A, with a monomer containing a functional group F, or a plurality of identical or different monomers containing identical or different functional groups F, and optionally, a monomer containing a segment U, or a plurality of identical or different monomers containing identical or different segments U, to form I, or with a monomer containing a unit (UFn2)o2, or a plurality of identical or different monomers containing identical or different units of the formula (UFn2)o2, to form II. The use of the polymers for coating dielectric materials, in particular dielectric waveguides, and optical signal transducers with dielectric waveguides coated by the polymers are also described. The optical signal transducers having a coated dielectric waveguides may be used for immobilizing chemical and/or biochemical recognition elements.

AN 2002:638105 HCAPLUS <<LOGINID::20081222>>
 DN 137:181915
 TI Phosphorus-containing polymers for optical signal transducers
 IN Dorn, Ingmar; Kohler, Burkhard
 PA Bayer Aktiengesellschaft, Germany
 SO U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020114604	A1	20020822	US 2002-81628	20020220
	US 7101945	B2	20060905		
	DE 10108483	A1	20020905	DE 2001-10108483	20010222
	CA 2438648	A1	20020906	CA 2002-2438648	20020211
	WO 2002068481	A1	20020906	WO 2002-EP1399	20020211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002238547	A1	20020912	AU 2002-238547	20020211
	AU 2002238547	B2	20070712		
	EP 1366088	A1	20031203	EP 2002-704708	20020211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004528414	T	20040916	JP 2002-567990	20020211
	US 20060287453	A1	20061221	US 2006-507329	20060821
PRAI	DE 2001-10108483	A	20010222		
	WO 2002-EP1399	W	20020211		
	US 2002-81628	A3	20020220		

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Phosphorylated polyhydroxy compounds for tartar control

AB An anticariogenic anticalculus dentifrice comprise an anticariogenic agent and an antitartar agent. The antitartar agent is formed by phosphorylation of a polyhydroxy compound with mol. weight ≤ 5000 kDa. The phosphorylated polyhydroxy compound has a molar substitution of ≤ 2 based on mol. weight of an average repeat unit in the starting polyhydroxy compound and possesses phosphate ester linkage satisfying at least 1 criteria of (a) ≥ 1 multi-substituted phosphate ester linked through an O to a single C of the polyhydroxy compound, and (b) ≥ 2 monophosphate groups separated by ≤ 3 C. Dextran (I) was added to a solution of polyphosphoric acid, tri-N-butylamine, and N,N-dimethylformamide and heated to 120° for 6h, then it was poured into EtOH. Saturated NaCl solution was added to the above mixture to aid polymer precipitation followed by purification and lyophilization of precipitate to obtain a white powder.

Formulation

of a toothpaste containing the phosphorylated I is given.

AN 1993:197835 HCAPLUS <<LOGINID::20081222>>

DN 118:197835

OREF 118:33861a,33864a

TI Phosphorylated polyhydroxy compounds for tartar control

IN Spaltro, Suree Methmanus; Aronson, Michael Paul

PA Unilever N. V., Neth.; Unilever PLC

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 512599	A2	19921111	EP 1992-201108	19920421
	EP 512599	A3	19930512		
	EP 512599	B1	19951220		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
	US 5202111	A	19930413	US 1991-697835	19910509
	AT 131721	T	19960115	AT 1992-201108	19920421
	ES 2082342	T3	19960316	ES 1992-201108	19920421
PRAI	US 1991-697835	A	19910509		

L4 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method for immobilizing polyphosphate-glucose phosphotransferase

AB The title method comprises incubating an inorg. carrier coated with a peptide for 20-30 h at $20-40^\circ$ with a $1-39^\circ$ buffered solution of Dextran Blue at pH 8.0, and then incubating the washed and dried adsorbent with a 0.1-0.3% solution of the enzyme at pH 8-9 and 4° for 25-50 h. The enzyme was immobilized on Dextran Blue-containing silica gel coated with collagen.

AN 1991:674631 HCAPLUS <<LOGINID::20081222>>

DN 115:274631

OREF 115:46534c,46536a

TI Method for immobilizing polyphosphate-glucose phosphotransferase

IN Kowalczyk, Tomasz; Szymona, Olga; Wolski, Tadeusz

PA Akademia Medyczna, Lublin, Pol.

SO Pol., 3 pp.

CODEN: POXXA7

DT Patent

LA Polish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	PL 152887	B1	19910228	PL 1987-265083	19870407
PRAI	PL 1987-265083		19870407		

L4 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI A reinvestigation of the phosphorylation of dextran with polyphosphoric acid: evidence for the formation of different types of phosphate moieties
 AB The products of phosphorylation of dextran with polyphosphoric acid were re-investigated by gel filtration, potentiometric titration, and ³¹P NMR spectroscopy. Mainly (80-88%) alkyl phosphates were formed together with alkyl diphosphates and dialkyl phosphates, the percentages of which depended on the duration of phosphorylation. Mild acid treatment of the crude samples hydrolyzed the diphosphates and gave products with >95% of monophosphate structures.
 AN 1989:194996 HCAPLUS <<LOGINID::20081222>>
 DN 110:194996
 OREF 110:32369a,32372a
 TI A reinvestigation of the phosphorylation of dextran with polyphosphoric acid: evidence for the formation of different types of phosphate moieties
 AU Sacco, Daniel; Klett-Zygmunt, Daniele; Dellacherie, Edith
 CS Lab. Chim.-Phys. Macromol., CNRS, Nancy, 54042, Fr.
 SO Carbohydrate Research (1988), 184, 193-202
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English

L4 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Interactions between dextran phosphates and human hemoglobin
 AB Dextran phosphates were prepared by direct phosphorylation of dextran of .hivin.Mw .simeq. 36,000 by means of polyphosphoric acid. This reaction gives rise to a mixture of structures containing at least 80-85% of diprotic monoesters such as ROPO₃H₂, the other structures being more complex in particular with crosslinking chains such as -OP(O)(OH)OP(O)(OH)-. These chains can be hydrolyzed in acidic conditions leading to polysaccharide derivs. containing phosphates essentially under the diprotic monoester form. These various compds., in the presence of Hb, provoke a decrease of its affinity for O and this effect increases with the phosphate substitution rate and with the amount of -OP(O)(OH)OP(O)(OH)- chains. The covalent fixation of these polyanionic dextrans onto Hb should lead to the oxygen-carrier conjugates with high mol. weight and low O affinity, useful in blood transfusion.
 AN 1988:443346 HCAPLUS <<LOGINID::20081222>>
 DN 109:43346
 OREF 109:7217a,7220a
 TI Interactions between dextran phosphates and human hemoglobin
 AU Zygmunt, D.; Labrude, P.; Vigneron, C.; Sacco, D.; Dellacherie, E.
 CS Lab. Chim. Phys. Macromol., ENSIC, Nancy, 54042, Fr.
 SO Journal de Chimie Physique et de Physico-Chimie Biologique (1988), 85(2), 315-18
 CODEN: JCPBAN; ISSN: 0021-7689
 DT Journal
 LA French

L4 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI A radioimmunoassay for guanosine-5'-diphosphate-3'-diphosphate and adenosine-5'-triphosphate-3'-diphosphate
 AB A radioimmunoassay for guanosine-5'-diphosphate-3'-diphosphate (pppGpp) and adenosine-5'-triphosphate-3'-diphosphate (pppApp) has been developed. The assay method is based on competition of an unlabeled highly phosphorylated nucleotide with 3H-labeled highly phosphorylated nucleotide for binding

sites on a specific antibody. Antibodies to ppGpp and pppApp were obtained by immunizing rabbits with the antigen prepared by conjugating ppGpp with human serum albumn using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, and with the antigen prepared by conjugating 8-(6-aminohexyl)amino-adenosine-5'-triphosphate-3'-diphosphate with human serum albumin using glutaraldehyde, resp. Antibody-bound 3H-labeled highly phosphorylated nucleotides were separated from the free 3H-labeled highly phosphorylated nucleotides by selective adsorption on dextran-coated charcoal. Displacement plots were linear over a concentration range of 5-1000 pmol/assay tube in a log-probit percent plot. Application of this method to biol. systems offers improved accuracy and convenience compared with the previous 32P04-labeling technique.

AN 1981:79698 HCAPLUS <<LOGINID::20081222>>

DN 94:79698

OREF 94:12939a,12942a

TI A radioimmunoassay for guanosine-5'-diphosphate-3'-diphosphate and adenosine-5'-triphosphate-3'-diphosphate

AU Hamagishi, Yasutaro; Oki, Toshikazu; Tone, Hiroshi; Inui, Taiji

CS Cent. Res. Lab., Sanraku-Ocean Co., Ltd., Fujisawa, 251, Japan

SO Journal of Biochemistry (Tokyo, Japan) (1980), 88(6), 1785-92

CODEN: JOBIAO; ISSN: 0021-924X

DT Journal

LA English

L4 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Esters of polysaccharides with phosphoric acid and palmitric acid

AB Water-soluble polysaccharides are treated with palmitic acid halide and phosphorylation reagents in the presence of tertiary amine in formamide solvent to obtain polysaccharide phosphate palmitates. The products are effective in controlling tumor growth. Thus, 1 part dextran (mol. weight 40,000) was dissolved in 100 parts formamide and to this were added Bu3N 20 and palmitoyl chloride 5.0 parts. The mixture was heated at 70° for 2 h and to this was added 5 parts polyphosphate. The mixture was allowed to stand at room temperature for 24 h and to this was added 400 parts MeOH. The precipitate was collected, washed with MeOH, and suspended in water. The pH of the suspension was adjusted to 10 with 10% NaOH and centrifuged. The supernatant was treated with 400 parts MeOH. The precipitate was collected, washed with MeOH, and dried in vacuo to obtain a water-soluble fraction. The water-soluble fraction (1 part) was dissolved in water and worked up to yield an dextran phosphate palmitate [63026-23-3]. The compound contained sugars 46.3, P 2.3, and palmitic acid 47.8%.

AN 1977:429017 HCAPLUS <<LOGINID::20081222>>

DN 87:29017

OREF 87:4551a,4554a

TI Esters of polysaccharides with phosphoric acid and palmitric acid

IN Suzuki, Shigeo; Suzuki, Masuko; Mikami, Takeshi

PA Kowa Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 52028583	A	19770303	JP 1975-104626	19750829
	JP 57056921	B	19821202		
PRAI	JP 1975-104626	A	19750829		

L4 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation and antitumor activity of O-palmitoyldextran phosphates, O-palmitoyldextrans, and dextran phosphate
 AB Three O-palmitoyldextran phosphates (PalDP) were prepared by esterification of dextran with palmitoyl chloride and polyphosphoric acid. One of the H₂O-insol. PalDP showed 82% growth regression against sarcoma 183 ascites-tumor in mice when administered at 1 mg/kg/day for 5 days. The H₂O-soluble PalDP showed 17% growth regression at the same dosage when administered alone and 83% when combined with mitomycin C. O-palmitoyldextrans and dextran phosphates were inactive in the inhibition of this ascites tumor. Thus, the existence of both fatty acid and phosphate groups is necessary to manifest antitumor activity in polysaccharides.
 AN 1977:406278 HCAPLUS <<LOGINID::20081222>>
 DN 87:6278
 OREF 87:1021a,1024a
 TI Preparation and antitumor activity of O-palmitoyldextran phosphates, O-palmitoyldextrans, and dextran phosphate
 AU Suzuki, Masuko; Mikami, Takeshi; Matsumoto, Tatsuji; Suzuki, Shigeo
 CS Dep. Microbiol., Tohoku Coll. Pharm., Sendai, Japan
 SO Carbohydrate Research (1977), 53(2), 223-9
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English

 L4 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Precipitation methods in plasma fractionation
 AB A review of recent developments in large-scale plasma fractionation techniques, some of which are applicable to routine laboratory work. Many different reagents may be used for the above purpose including organic solvents, (NH₄)₂SO₄, synthetic organic compds., and natural products such as amino and fatty acids, phytoagglutinins, and tannic acid. Future plasma fractionation may use as many reagents as those already proposed for the separation of lipoproteins: heparin dextran sulfate, gelatin, phytic acid, uric acid, phosphotungstate, polyphosphate, poly(vinylpyrrolidinone), polyethylene glycol, anionic detergents, cationic detergents, chlortetracycline, oxytetracycline, leucocyanidol. Precipitating agents should not destroy the mol. amount of the protein being separated
 by using extreme pH values. A suitable reagent not only leaves the protein structure intact, but must also be easily removed, and the trace amts. remaining should be innocuous in the human organism. 76 refs.
 AN 1972:485995 HCAPLUS <<LOGINID::20081222>>
 DN 77:85995
 OREF 77:14177a,14180a
 TI Precipitation methods in plasma fractionation
 AU Steinbuch, M.
 CS Cent. Natl. Transfus. Sang., Paris, Fr.
 SO Vox Sanguinis (1972), 23(1), 92-106
 CODEN: VOSAAD; ISSN: 0042-9007
 DT Journal; General Review
 LA English

 => s molecular weight
 1328116 MOLECULAR
 168516 WEIGHT
 L5 74419 MOLECULAR WEIGHT
 (MOLECULAR(W)WEIGHT)

=> s 12 and 15
L6 13 L2 AND L5

=> s 16 and (PY<2003 or AY<2003 or PRY<2003)
22962889 PY<2003
4501251 AY<2003
3969814 PRY<2003
L7 10 L6 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d 17 1-10 ti abs bib

L7 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Porous beta-tricalcium phosphate granules for bone implantation, and methods for producing same
AB A porous β -tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are sep. discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm , preferably 50-125 μm . The porous β -TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous β -TCP, and a bioactive agent and a binder. The invention also provides an implementable prosthetic device comprising a prosthetic implant having a surface region, a porous β -TCP material disposed on the surface region optionally comprising at least a bioactive agent or a binder. Methods of producing the porous β -TCP material and including bone formation are also provided.

AN 2002:695831 HCAPLUS <<LOGINID::20081222>>

DN 137:237785

TI Porous beta-tricalcium phosphate granules for bone implantation, and methods for producing same

IN Dalal, Paresh S.; Dimaano, Godofredo R.; Toth, Carol Ann; Kulkarni, Shailesh C.

PA Stryker Corporation, USA

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002070029	A2	20020912	WO 2002-US5827	20020226 <--
	WO 2002070029	A3	20030206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20030049328	A1	20030313	US 2001-798518	20010302 <--
	US 20030180376	A1	20030925	US 2001-960789	20010921 <--
	US 6949251	B2	20050927		
	CA 2439813	A1	20020912	CA 2002-2439813	20020226 <--
	AU 2002306592	A1	20020919	AU 2002-306592	20020226 <--
	EP 1372748	A2	20040102	EP 2002-748362	20020226 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2005505311	T	20050224 JP 2002-569200 20020226 <--
PRAI	US 2001-798518	A	20010302 <--
	US 2001-960789	A	20010921 <--
	WO 2002-US5827	W	20020226 <--

L7 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Effect of dextran molecular weight on protein stabilization during freeze-drying and storage

AB The effect of dextran mol. weight on structural stability of freeze-dried products and protein stability in amorphous matrixes was investigated during storage at elevated temps. Glucose-6-phosphate dehydrogenase (G6PDH) was freeze-dried in 10% dextrans of 5 mol. wts. (12, 42, 71, 512, and 2000 kD) to residual water content of 0.027g/g dry mass. The mol. weight of dextrans affected the glass transition temperature (Tg) of freeze-dried products and the recovery of enzyme activity after freeze-drying. As the mol. weight of dextrans increased from 12 to 2000 kD, the Tg increased from 100 to 120°, whereas the recovery of protein activity decreased from 85 to 70%. The inactivation of freeze-dried protein during storage followed a bi-phasic first-order kinetics. The stability of amorphous matrixes and protein increased significantly as the mol. weight increased from 12 to 512 kD. However, at a higher mol. weight (2000 kD), the stability was reduced. In a sep. experiment, the stability of dried dextran/protein samples was studied during heating from 30 to 99° at 0.2°/min and subsequent incubation at 99°. Dextran with an average mol. weight of 512 kD again provided the best protection. Mechanisms that cause the differences in protein stability among different mol. weight dextrans remain unclear.

AN 2001:923070 HCAPLUS <<LOGINID::20081222>>

DN 137:129693

TI Effect of dextran molecular weight on protein stabilization during freeze-drying and storage

AU Sun, Wendell Q.; Davidson, Paul

CS Department of Biological Sciences, National University of Singapore, Singapore, 119260, Singapore

SO Cryo-Letters (2001), 22(5), 285-292

CODEN: CRLED9; ISSN: 0143-2044

PB Cryo-Letters

DT Journal

LA English

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Critical Molecular Weight Effects in the Aggregation of Phospholipid Vesicles Triggered by Water-Soluble Polymers and an Integrated Glycolipid

AB The intervesicular aggregation of phospholipid vesicles is induced by the addition of water-soluble polymers such as polyethylene glycol, dextran, etc. due to the interaction between the vesicular surface and the water-soluble polymers. The interaction can be expressed by the critical mol. weight (Mc) of the water-soluble polymers for the aggregation of vesicles. The surface modification of vesicles with glycolipids [01,05-bis(octadecyl) N-maltooligonoyl-L-glutamate] accelerates the aggregation of vesicles induced by dextran; therefore, Mc significantly decreased due to the surface modification. No dependence of phospholipid concentration and dextran concentration in an aqueous phase on the Mc indicates that dextran does not act as a crosslinking agent among the vesicles. A clear dependence of the d. of the saccharide chains on the vesicular surface on the Mc suggests that dextran should adsorb on the surface of the vesicles by the interaction with the oligosaccharide chains on the surface and

cause vesicular aggregation. A lower critical solution temperature was observed for this kind of interaction, and the critical temperature was controlled by changing the mol. weight of dextran.

AN 1996:672694 HCAPLUS <<LOGINID::20081222>>

DN 126:11474

OREF 126:2375a,2378a

TI Critical Molecular Weight Effects in the Aggregation of Phospholipid Vesicles Triggered by Water-Soluble Polymers and an Integrated Glycolipid

AU Takeoka, Shinji; Sou, Keitaro; Arase, Shinya; Ohgushi, Takeru; Tsuchida, Eishun

CS Advanced Research Institute for Science and Engineering, Waseda University, Tokyo, 169, Japan

SO Macromolecules (1996), 29(25), 8132-8136

CODEN: MAMOBX; ISSN: 0024-9297

PB American Chemical Society

DT Journal

LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Organ preservation solutions containing low molecular weight dextrans

AB An organ preservation solution containing a low mol. weight dextran in a pharmacol.

acceptable storage solution is prepared for storage and preservation of organs for transplantation. A preservation solution contained sodium 141, phosphate 79, dextran (mol. weight = 5000-10,000) 30 mmol/L. Rat kidneys stored in the above solution exhibited no significant necrosis after 5 days of cold storage, while those stored in Euro-Collins solution exhibited total necrosis of most of the cortical unriniferous tubules following 3 days of cold storage.

AN 1994:331166 HCAPLUS <<LOGINID::20081222>>

DN 120:331166

OREF 120:58099a,58102a

TI Organ preservation solutions containing low molecular weight dextrans

IN Andrews, Peter

PA Georgetown University, USA

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5306711	A	19940426	US 1992-903477	19920624 <--
PRAI	US 1992-903477		19920624	<--	

L7 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Recovery of enzyme/protein using liquid-liquid extraction

AB Partition coeffs. of a series of amino acids and some proteins (Kaa and Kpr) with various relative hydrophobicities have been determined at their isoelec. points (PI) in the aqueous 2-phase systems, PEG (polyethylene glycol)/DEX (dextran) and PEG/PK (potassium phosphates), varying mol. weight (MW) and concentration of the phase-forming polymer. Hydrophobicity factor HF of these phase systems, defined as the increment of Kaa with changes in the relative hydrophobicity of amino acids used,

are correlated with MW and concentration of PEG, and further, with Kpr regardless

of the phase system. Partition coeffs. of proteins can be varied and manipulated according to these correlations.

AN 1989:611392 HCAPLUS <<LOGINID::20081222>>

DN 111:211392

OREF 111:34983a,34986a

TI Recovery of enzyme/protein using liquid-liquid extraction

AU Kuboi, Ryoichi; Wang, Wei Hong; Tanaka, Hisakazu; Komasa, Isao

CS Fac. Eng. Sci., Osaka Univ., Osaka, 560, Japan

SO Proc. Symp. Solvent Extr. (1988), 197-198.5 Publisher: Jpn.

Assoc. Solvent Extr., Hamamatsu, Japan.

CODEN: 56PBAF

DT Conference

LA English

L7 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acid-base properties and molecular-weight distribution of aminoalkylthiol and aminoalkylthiophosphate derivatives of dextrans
GI For diagram(s), see printed CA Issue.

AB The mol. wts. and polydispersion of aminoalkylthiol I [R = CH₂NH(CH₂)₃NH(CH₂)₂SH] and aminoalkylthiophosphate I [R = CH₂N(CH₂)₃NH(CH₂)₂SPO₃H] (mol. weight 20000-60000) dextran derivs. show little or no change compared to the starting dextran dialdehyde. The pK_a value of the thiol group in aqueous solns. of dextran aminoalkylthiol derivs. decreases with increasing degree of modification of dextran with similar mol. wts. compared to low-mol. weight aminoalkylthiols.

AN 1984:611597 HCAPLUS <<LOGINID::20081222>>

DN 101:211597

OREF 101:32079a,32082a

TI Acid-base properties and molecular-weight distribution of aminoalkylthiol and aminoalkylthiophosphate derivatives of dextrans

AU Bondarev, G. N.; Drobchenko, S. N.

CS Leningr. Inst. Yad. Fiz., Leningrad, USSR

SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1984), (5), 1034-8

CODEN: IASKA6; ISSN: 0002-3353

DT Journal

LA Russian

L7 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Characterization of human cytomegalovirus DNA: infectivity and molecular weight

AB Human cytomegalovirus DNA was isolated from purified virions, subjected to sucrose d.-gradient centrifugation, and examined by electron microscopy. The viral DNA mols. were linear and had a length of 76.22 μ m, corresponding to a mol. weight of 147.13 + 106 daltons. The DNA was infectious when tested in human embryonic lung cells using the DEAE-dextran and the Ca phosphate techniques. The d. in CsCl was 1.717 g/cm³.

AN 1979:571305 HCAPLUS <<LOGINID::20081222>>

DN 91:171305

OREF 91:27621a,27624a

TI Characterization of human cytomegalovirus DNA: infectivity and molecular weight

AU Geelen, J. L. M. C.; Walig, C.; Wertheim, P.; Van der Noordaa, J.

CS Lab. Gezondheidsleer, Univ. Amsterdam, Amsterdam, Neth.

SO IARC Scientific Publications (1978), 24(Oncogenesis

Herpesviruses 3, Pt. 1), 97-103

CODEN: IARCCD; ISSN: 0300-5038

DT Journal

LA English

L7 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Aggregation of liposomes by Dextrans of high molecular weight

AB Sonicated dispersions (liposomes) of natural and synthetic phospholipids are aggregated reversibly by dextrans 40, 110, and 500. The dextran concentration required for aggregation is dependent on chain length, lipid composition of the liposome, and, for ionically-charged phospholipids, the ionic strength of the medium. Apparently, adsorption of dextrans to the erythrocyte surface can occur by interaction with surface phospholipid substituents.

AN 1979:35233 HCAPLUS <<LOGINID::20081222>>

DN 90:35233

OREF 90:5631a,5634a

TI Aggregation of liposomes by Dextrans of high molecular weight

AU Schachter, David

CS Dep. Physiol., Columbia Univ. Coll. Physicians Surg., New York, NY, USA

SO Biochemical and Biophysical Research Communications (1978), 84(4), 840-4
CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

L7 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Histochemical method for the demonstration of the activity of α -glucan phosphorylase. II. Relation of molecular weight of glucosyl acceptor dextran to activation of phosphorylase

AB Biochem. and histochem. investigation of the activity and localization of α -glucan phosphorylase in exptl. glycogen-depleted canine heart tissue, using dextran as enzyme acceptor, shows that only linear unbranched dextrans have acceptor properties. Michaelis-Menten constant detns. indicate that the enzyme affinity for dextran nonreducing end groups increases with increasing mol. weight of the acceptor. In glycogen-depleted tissue of anoxic and ischemic cardiac musculature there is gradual inactivation of the enzyme during the ischemic period and shortly before total inactivation the enzyme affinity for lower mol. weight dextran fractions is greatly reduced. It is therefore essential to use a high mol. weight unbranched dextran fraction in histochem. demonstration of phosphorylase activity in infarcted areas of the heart.

AN 1969:44355 HCAPLUS <<LOGINID::20081222>>

DN 70:44355

OREF 70:8313a,8316a

TI Histochemical method for the demonstration of the activity of α -glucan phosphorylase. II. Relation of molecular weight of glucosyl acceptor dextran to activation of phosphorylase

AU Meijer, A. E. F. H.

CS Univ. Amsterdam, Amsterdam, Neth.

SO Histochemie (1968), 16, 134-43
CODEN: HICHAU; ISSN: 0018-2222

DT Journal

LA English

L7 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Viscosimetric dextran molecular weight determination in intermediate products in the production of clinical materials

AB In the determination of the limiting viscosity as a measure of the average
mol. weight of
dextran and intermediate products, no alc. can be present since this leads
to too high a value for the limiting viscosity. Monosaccharides and NaCl
have a negligible effect. Decomposition products of proteins have a marked
influence on the limiting viscosity. The addition of phosphate buffer is
rejected because it causes the limiting viscosity values to be too high.

AN 1965:50693 HCAPLUS <<LOGINID::20081222>>
DN 62:50693
OREF 62:8932h,8933a
TI Viscosimetric dextran molecular weight determination
in intermediate products in the production of clinical materials
AU Vavra, Ivan; Vavra, Ankica; Bajalovic, Ivan
CS Rudar. Fak, Belgrade
SO Acta Pharmaceutica Jugoslavica (1962), 12, 129-37
From: CZ 1964(33), Abstr. No. 1463.
CODEN: APJUA8; ISSN: 0001-6667
DT Journal
LA Croatian

=> d his

(FILE 'HOME' ENTERED AT 09:11:47 ON 22 DEC 2008)

FILE 'HCAPLUS' ENTERED AT 09:12:22 ON 22 DEC 2008

L1 1123946 S IMMUN?
L2 800 S DEXTRAN(6A)PHOSPH?
L3 31511 S POLYPHOSPHATE OR POLYPHOSPHORIC
L4 13 S L2 AND L3
L5 74419 S MOLECULAR WEIGHT
L6 13 S L2 AND L5
L7 10 S L6 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	72.31	72.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-18.40	-18.40

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:13:50 ON 22 DEC 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 10:18:04 ON 22 DEC 2008
FILE 'HCAPLUS' ENTERED AT 10:18:04 ON 22 DEC 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	75.00	75.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-18.40	-18.40

=> s 11 and 12
L8 93 L1 AND L2

=> s 18 and (PY<2003 or AY<2003 or PRY<2003)
22962889 PY<2003
4501251 AY<2003
3969814 PRY<2003
L9 69 L8 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s 19 and 15
L10 0 L9 AND L5

=> s degree or phosphorylation
4509676 DEGREE
186292 PHOSPHORYLATION
L11 4685617 DEGREE OR PHOSPHORYLATION

=> s 19 and 111
L12 5 L9 AND L11

=> d 112 1-5 ti abs bib

L12 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Phosphorylated sugar alcohols from basidiomycetes and dextran as antiviral drugs and health foods
AB Phosphorylated sugar alcs. (including β -glucan)from basidiomycetes and dextran prepared by pretreatment with ZnCl₂ and urea melting or enzyme method are claimed as antiviral drugs (e.g. against HIV1) and health foods.
AN 2003:166958 HCAPLUS <<LOGINID::20081222>>
DN 138:163508
TI Phosphorylated sugar alcohols from basidiomycetes and dextran as antiviral drugs and health foods
IN Akabane, Toru; Kitani, Yoshiyasu; Baba, Masanori; Tadano, Toshio
PA Uma K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003063968	A	20030305	JP 2001-295057	20010823 <--
PRAI JP 2001-295057		20010823	<--	

L12 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Intestinal infection with Giardia spp. reduces epithelial barrier function in a myosin light chain kinase-dependent fashion
AB Giardiasis causes malabsorptive diarrhea, and symptoms can be present in the absence of any significant morphol. injury to the intestinal mucosa. The effects of giardiasis on epithelial permeability in vivo remain unknown, and the role of T cells and myosin light chain kinase (MLCK) in altered intestinal barrier function is unclear. This study was conducted

to determine whether *Giardia* spp. alters intestinal permeability in vivo, to assess whether these abnormalities are dependent on T cells, and to assess the role of MLCK in altered epithelial barrier function. Immunocompetent and isogenic athymic mice were inoculated with axenic *Giardia muris* trophozoites or sterile vehicle (control), then assessed for trophozoite colonization and gastrointestinal permeability. Mechanistic studies using nontransformed human duodenal epithelial monolayers (SCBN) determined the effects of *Giardia* on myosin light chain (MLC) phosphorylation, transepithelial fluorescein isothiocyanate-dextran fluxes, cytoskeletal F-actin, tight junctional zonula occludens-1 (ZO-1), and MLCK. *Giardia* infection caused a significant increase in small intestinal, but not gastric or colonic, permeability that correlated with trophozoite colonization in both immunocompetent and athymic mice. In vitro, *Giardia* increased permeability and phosphorylation of MLC and reorganized F-actin and ZO-1. These alterations were abolished with an MLCK inhibitor. Conclusions: Disruption of small intestinal barrier function is T cell independent, disappears on parasite clearance, and correlates with reorganization of cytoskeletal F-actin and tight junctional ZO-1 in an MLCK-dependent fashion.

AN 2002:839408 HCAPLUS <<LOGINID::20081222>>

DN 138:120766

TI Intestinal infection with *Giardia* spp. reduces epithelial barrier function in a myosin light chain kinase-dependent fashion

AU Scott, Kevin G.-E.; Meddings, Jonathon B.; Kirk, David R.; Lees-Miller, Susan P.; Buret, Andre G.

CS Department of Biological Sciences, University of Calgary, AB, Can.

SO Gastroenterology (2002), 123(4), 1179-1190

CODEN: GASTAB; ISSN: 0016-5085

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Dextran Sulfate Inhibits IFN- γ -Induced Jak-Stat Pathway in Human Vascular Endothelial Cells

AB Human vascular endothelial cells can be induced by IFN- γ to express class II MHC proteins. Previously, dextran sulfate was shown to selectively inhibit expression of class II MHC by preventing transcription of the gene encoding CIITA, a transactivator protein required for IFN- γ -inducible expression of class II genes. Here, the authors characterized the effects of dextran sulfate on the intracellular events occurring prior to CIITA activation. Immunopptn. and Western blot analyses indicated that IFN- γ -induced phosphorylation of Stat1 and Jak2 was blocked by dextran sulfate. In addition, electron micrographs showing the large accumulation of dextran sulfate particles in the cytoplasms of endothelial cells demonstrated that Stat and Jak proteins may directly interact with dextran sulfate. Binding of radiolabeled IFN- γ to cells indicated that dextran sulfate may also modulate IFN- γ interactions with the cell surface. Thus, dextran sulfate is capable of interfering with the IFN- γ -induced expression of class II MHC genes at multiple sites. (c) 1999 Academic Press.

AN 1999:191152 HCAPLUS <<LOGINID::20081222>>

DN 131:39387

TI Dextran Sulfate Inhibits IFN- γ -Induced Jak-Stat Pathway in Human Vascular Endothelial Cells

AU Lian, Rebecca H.; Kotwal, Girish J.; Hunt, Lawrence A.; Wilson, Mark A.; Justus, David E.

CS Department of Microbiology and Immunology, University of Louisville School

of Medicine, Louisville, KY, 40292, USA
SO Cellular Immunology (1999), 192(2), 140-148
CODEN: CLIMB8; ISSN: 0008-8749
PB Academic Press
DT Journal
LA English

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
TI cAMP-mediated phosphorylation of the low-Km cAMP
phosphodiesterase markedly stimulates its catalytic activity
AB Treatment of intact human platelets with the adenylate cyclase agonist
forskolin (100 μ M) resulted in an increase in cAMP phosphodiesterase
activity in freeze-thaw lysates. When the low-Km (high affinity),
cGMP-inhibited cAMP phosphodiesterase was isolated from such lysates by
blue dextran-Sepharose chromatog., the specific activity of the enzyme was
increased an average of 11-fold over similarly processed control platelets.
The increase in the low-Km, cGMP-inhibited cAMP phosphodiesterase activity
was inhibited when platelets were incubated with the protein kinase
inhibitor H 8 prior to treatment with forskolin, suggesting that the
stimulation of cAMP phosphodiesterase activity involved a cAMP-dependent
phosphorylation. When intact platelets that had been prelabeled
with inorg. [32P]phosphate were treated with forskolin and the low-Km,
cGMP-inhibited phosphodiesterase was isolated by blue
dextran-Sepharose chromatog., a protein of 110,000 kDa was
phosphorylated. By using a monospecific antiserum to the purified
phosphodiesterase, this protein was shown to be the low-Km, cGMP-inhibited
cAMP phosphodiesterase by Western blot anal. and by immunopptn.
The stable prostacyclin analog iloprost also stimulated the low-Km cAMP
phosphodiesterase activity .apprx.2-fold and caused
phosphorylation of the enzyme. Apparently,
phosphorylation of the low-Km, cGMP-inhibited phosphodiesterase
may be an important regulatory mechanism for this enzyme in platelets.

AN 1989:54985 HCAPLUS <<LOGINID::20081222>>

DN 110:54985

OREF 110:9053a,9056a

TI cAMP-mediated phosphorylation of the low-Km cAMP
phosphodiesterase markedly stimulates its catalytic activity

AU Grant, Paul G.; Mannarino, Anthony F.; Colman, Robert W.

CS Sch. Med., Temple Univ., Philadelphia, PA, 19140, USA

SO Proceedings of the National Academy of Sciences of the United States of
America (1988), 85(23), 9071-5

CODEN: PNASA6; ISSN: 0027-8424

DT Journal

LA English

L12 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Dextran derivatives in single and combination chemotherapy against
transplantable mouse ascites and solid tumors

AB Dextran was modified by palmitoylation and/or
phosphorylation to yield 3 derivs.:palmitoyldextran
phosphate [63026-23-3] dextran phosphate
[9041-77-4], and palmitoyldextran [63026-27-7]. Of these compds., only
palmitoyldextran phosphate showed growth-inhibitory activity against
Ehrlich solid tumor in mice. In combination therapy with mitomycin C
[50-07-7], bleomycin [11056-06-7], cyclophosphamide [50-18-0], and
5-fluorouracil [51-21-8], palmitoyldextran phosphate manifested strong
synergistic effects against both Sarcoma 180 ascites and L1210 leukemic
tumors. The compound was not directly cytotoxic against Sarcoma 180 ascites
tumor, but it appeared to act via activation of peritoneal macrophage.

The antitumor activity of palmitoyldextran phosphate apparently is mainly due to immunol. host-mediated mechanisms.

AN 1977:593864 HCAPLUS <<LOGINID::20081222>>

DN 87:193864

OREF 87:30571a,30574a

TI Dextran derivatives in single and combination chemotherapy against transplantable mouse ascites and solid tumors

AU Suzuki, Masuko; Mikami, Takeshi; Kadowaki, Minoru; Matsumoto, Tatsuji; Suzuki, Shigeo

CS Dep. Microbiol., Tohoku Coll. Pharm., Sendai, Japan

SO Cancer Research (1977), 37(9), 3448-54

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English